Patents Assigned to Sanford-Burnham Medical Research Institute
  • Sulfonamide compounds and uses as TNAP inhibitors
    Patent number: 9884826
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 6, 2018
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
  • Delivery of agents using interfering nanoparticles
    Patent number: 9878050
    Abstract: Provided are compositions and methods for delivery of therapeutic agents, such as chemically stabilized antisense oligonucleotides useful in RNA silencing. The compositions include interfering nanoparticles (iNOPs) associated with one or more agents. Several functional iNOP derivatives are provided which allow for targeted delivery of agents to specific cell types as well as exhibiting reduced cellular toxicity.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Tariq M. Rana
  • Small molecule agonists of neurotensin receptor 1
    Patent number: 9868707
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 16, 2018
    Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, DUKE UNIVERSITY
    Inventors: Anthony Pinkerton, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla, Michael Hedrick, Lawrence Barak, Marc Caron
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20170342088
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: August 25, 2015
    Publication date: November 30, 2017
    Applicants: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, YALE UNIVERSITY
    Inventors: REUBEN J. SHAW, DANIEL F. EGAN, NICHOLAS COSFORD, BENJAMIN TURK, MITCHELL VAMOS, DHANYA RAVEENDRA PANICKAR, MATTHEW CHUN, DOUG SHEFFLER
  • Compositions and methods for targeted endometriosis treatment
    Patent number: 9783576
    Abstract: Disclosed are compositions and methods for selectively targeting an endometriosis cell. Also disclosed are compositions and methods for treating endometriosis.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: October 10, 2017
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Michiko Fukuda, Kazuhiro Sugihara
  • EBI2 modulators
    Patent number: 9776979
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 3, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Compounds and methods for activating the apoptotic arm of the unfolded protein response
    Patent number: 9732067
    Abstract: N-substituted sulfonylphenyl-5-mitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provided as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: August 15, 2017
    Assignees: University of Kansas, Sanford-Burnham Medical Research Institute, The Regents of the University of Michigan, Wayne State University
    Inventors: Jennifer E. Golden, Jeffrey Aube, Daniel P. Flaherty, Andrew M. Fribley, Randal J. Kaufman, Thomas D. Y. Chung, Anthony B. Pinkerton, Michael Pablo Hedrick
  • Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof
    Publication number: 20170217951
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: June 9, 2015
    Publication date: August 3, 2017
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Nicholas David Peter COSFORD, DHANYA Raveendra-Panickar, Douglas J. SHEFFLER
  • LONG NON-CODING RNA AS A DIAGNOSTIC AND THERAPEUTIC AGENT
    Publication number: 20170166972
    Abstract: Provided herein are methods for the diagnosis of cancer by comparison of a quantification of long non-coding RNA with the same measurement taken in a reference sample from a healthy patient. Further provided herein are methods of anticipating the likelihood that such a disease will develop, and methods of treatment in the event of such development.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 15, 2017
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventor: Ranjan Perera
  • Methods and compositions related to a retinoid receptor-selective pathway
    Patent number: 9611235
    Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: April 4, 2017
    Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, XIAMEN UNIVERSITY
    Inventors: Xiao-kun Zhang, Ying Su, Hu Zhou, Wen Liu, Pei-Qiang Huang
  • Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
    Patent number: 9598402
    Abstract: Provided is a process for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 21, 2017
    Assignees: Southern Research Institute, Sanford-Burnham Medical Research Institute
    Inventors: Marintha L. Heil, Nicholas D. P. Cosford, Robert Ardecky, Jiwen Zou
  • Diagnosis and treatment of brain tumor
    Patent number: 9581598
    Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: February 28, 2017
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Pirjo Laakkonen
  • Inhibitor of apoptosis protein (IAP) antagonists
    Patent number: 9546174
    Abstract: Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: January 17, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Nicholas David Peter Cosford, Mitchell Dennis Vamos
  • Methods and compositions related to targeting tumors and wounds
    Patent number: 9522198
    Abstract: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sties of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: December 20, 2016
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Jan Pilch
  • LONG NON-CODING RNA SPRY4-IT1 AS A DIAGNOSTIC AND THERAPEUTIC AGENT
    Publication number: 20160346311
    Abstract: Provided herein are methods for the diagnosis of cancer by comparison of a quantification of long non-coding RNA SPRY4-IT1 with the same measurement taken in a reference sample from a healthy patient. Further provided herein are methods of anticipating the likelihood that such a disease will develop, and methods of treatment in the event of such development.
    Type: Application
    Filed: March 31, 2016
    Publication date: December 1, 2016
    Applicant: Sanford-Burnham Medical Research Institute
    Inventor: Ranjan Perera
  • MIR-211 EXPRESSION AND RELATED PATHWAYS IN HUMAN MELANOMA
    Publication number: 20160340744
    Abstract: Provided herein are methods for the diagnosis of human melanoma by assessing MITF, miR-211, TRPM1, and/or KCNMA1 and methods for the diagnosis of resistance to chemotherapeutic agents by assessing the regulatory pathways of PGC1?. Methods for treating melanoma, including drug-resistant melanoma, are also provided.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 24, 2016
    Applicant: Sanford-Burnham Medical Research Institute
    Inventor: Ranjan Perera
  • Sulfonamide compounds and uses as TNAP inhibitors
    Patent number: 9458147
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 4, 2016
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D. P. Cosford, Jose Luis Millan
  • Method and compounds for generation of iPSCs
    Patent number: 9410128
    Abstract: The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: August 9, 2016
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Tariq M. Rana
  • HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
    Patent number: 9320810
    Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: April 26, 2016
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
  • Inhibitors of Furin and other pro-protein convertases
    Patent number: 9266828
    Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 23, 2016
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Alex Strongin, Maurizio Pellecchia, Elisa Barile